Disc Medicine
NASDAQ · IRON·Watertown, MA·Small-cap·Phase 3
Clinical-stage biotech focused on hematologic diseases. Lead asset bitopertin is a glycine transporter inhibitor in Phase 3 for erythropoietic protoporphyria (EPP); pipeline includes DISC-0974 (anti-hemojuvelin) and DISC-3405.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Disc Medicine Corporate Presentation | Corporate overview | April 15, 2026 | 58 |